[Ip-health] Will USTR undermine Obama on biosimilars at Trans-Pacific trade negotiations?

Ruth Lopert ruth.lopert at gmail.com
Fri May 27 20:37:37 PDT 2011

Oh my. Actually the PPACA provides only 4 years of data exclusivity, but 12
years of market exclusivity (12 years of data exclusivity would be even
worse)  And they are not patent protections. And the exclusivity applies to
the originator, not the biosimilar.

And they wont get it anyway.


On Fri, May 27, 2011 at 4:08 PM, Peter Maybarduk <pmaybarduk at citizen.org>wrote:

> Inside U.S. Trade - 05/27/2011
> USTR Signals Support For Longer Data Protection For Biologics In TPP
> Posted: May 26, 2011
> The Office of the U.S. Trade Representative signaled last week it will
> pursue stronger patent protections for biosimilar drugs than for
> conventional medicines in the Trans-Pacific Partnership (TPP) negotiations,
> as demanded by U.S. pharmaceutical companies, according to informed sources.
> In a May 20 briefing for private-sector stakeholders, USTR officials
> indicated they may propose granting as much as 12 years of data exclusivity
> for biosimilar drugs -- also known as biologics -- these sources said. The
> officials, however, did not fully commit to doing so, they said.
> A 12-year data exclusivity period would reflect provisions in the U.S.
> health care reform bill that was signed into law last year. At the same
> time, the officials said they were aware of the fact that President Obama's
> fiscal year 2012 budget proposal called for a reduction of the data
> exclusivity period for biologics to seven years.
> Either of these periods would be a jump up from the five years of data
> exclusivity for pharmaceuticals that the United States has negotiated in
> past trade deals.
> During the data exclusivity period, generic drug manufacturers are barred
> from accessing the clinical data typically generated by brand-name drug
> companies. This delays the marketing of cheaper, generic competitor drugs.
> The Pharmaceutical Research and Manufacturers of America (PhRMA), the
> Biotechnology Industry Organization (BIO) and others are urging USTR to
> secure 12 years of data exclusivity for biologics in the TPP talks in order
> to match the provisions of U.S. law (Inside U.S. Trade, April 29).
> "We seek reciprocity in trade agreements," said Lila Feisee, vice president
> of global intellectual property at the Biotechnology Industry Organization.
> "There should be reciprocity in our trade partners as well."
> This would mean the eight other TPP parties would be expected to adopt the
> same 12-year data exclusivity period for biologics.
> A private-sector source pointed out that the negotiating objectives in the
> 2002 fast-track law, which has expired, states that negotiators should
> ensure that any IPR measure should "reflect a standard of protection similar
> to that found in United States law."
> The USTR officials in the briefing did not say for certain whether the
> United States will table a complete proposal on intellectual property rights
> (IPR) before the next round of TPP negotiations in Vietnam scheduled for
> mid-June, but signaled that they are working toward this goal, at least with
> respect to pharmaceutical patent provisions, sources said.
> In a related development, Assistant USTR for IPR Stan McCoy did not commit
> to making a complete IPR proposal by the Vietnam round. At a May 16 event,
> he said it is difficult "to say with certainty what we're going to do when."
> "The next round will be in Vietnam and we're looking at what we can table
> for that round and it's all kind of an ongoing process inside the
> administration," McCoy said. USTR has already tabled most of its proposed
> IPR text, but has not yet tabled the most crucial provisions on patent
> protections and other IPR topics.
> At the briefing, one USTR official made it "very clear" that the U.S.
> government does not intend to replicate the patent provisions in the May 10
> agreement, one informed source said. That agreement, struck in 2007 between
> House Democrats and the Bush administration, eased requirements for data
> exclusivity for conventional drugs, patent linkage and patent term extension
> in the FTAs with Panama, Peru and Colombia to improve access for affordable
> medicines.
> The official said that "2007 was 2007," and "2011 is 2011," in an apparent
> signal that the 2007 deal as negotiated is not directly relevant for the TPP
> deal, sources said.
> For instance, USTR noted that new domestic legislation, such as the health
> care reform bill establishing a 12-year data exclusivity for biologics, is
> one example of how the circumstances differ now when considering whether the
> May 10 standards are still relevant for TPP, sources said.
> The pharmaceutical industry has launched a major lobbying campaign to get
> USTR to disregard the May 10 deal and make the U.S.-Korea FTA the basis of
> its TPP proposals on pharmaceuticals (Inside U.S. Trade, April 29).
> In the briefing, USTR said that it has not yet tabled text on
> pharmaceutical pricing and reimbursement policies, but said it is under
> consideration. But USTR gave no clues on whether such provisions would stand
> as a separate chapter or if they would be included in other chapters,
> sources said.
> Industry wants these provisions to be included as a way to mandate more
> transparency for or altogether counteract national drug pricing programs,
> which they say can restrict market access and profits for U.S. drug
> companies.
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

More information about the Ip-health mailing list